Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Tamura

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Journal of Gastroenterology|June 5, 2001
HBV-related fulminant hepatic failure: successful intensive medical therapy in a candidate for liver transplantationM Masuhara, T Yagawa, M Aoyagi, et al.
Targeted Oncology|May 27, 2014
Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancerT Kogawa, A Doi, M Shimokawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Journal of Gastroenterology|June 5, 2001
HBV-related fulminant hepatic failure: successful intensive medical therapy in a candidate for liver transplantationM Masuhara, T Yagawa, M Aoyagi, et al.
Targeted Oncology|May 27, 2014
Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancerT Kogawa, A Doi, M Shimokawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Pageof 4